gip glp 1 agonist Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes Effects of tirzepatide, a dual

Delayed gastric emptying was the most common problem (80% of patients), while 33% had slower small bowel and colon transit [29]

Interaction of DPP4 with FAP leads to a local degradation of ECM and thus migration and invasion of endothelial cells (37)

Potential side effects (long-term?) In the recent history of GLP1 development and in light of millions of people who have used them for a long period of time, concerns for long-term side effects have made news headlines several times, however, large studies and long term follow-up of users have not revealed any definitive long term risks Maintaining muscle and losing more fat - step-by-step guide

Some physicians are saying it

Obes Facts 10(3):160167 Mozaffarian D, Agarwal M, Aggarwal M, Alexander L, Apovian CM, Bindlish S et al (2025) Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American college of lifestyle medicine, the American society for Nutrition, the obesity medicine Association, and the obesity society

When compared to controls, the two drugs efficiently reduced glycemia and weight in T2D, obesity, or both